SBH Sciences brings over 25 years of oncology expertise, working collaboratively with pharma, biotech, and diagnostic companies to transform promising ideas into breakthrough treatments. Our comprehensive portfolio features 450 mammalian cell lines, including 400 human cancer cell lines and numerous primary human cells. This positions us to advance your anticancer therapy to market. In addition to this extensive cell line library, we offer advanced in vitro cytotoxicity testing and customized assay development, delivering end-to-end solutions to accelerate your complex drug development efforts.
We routinely perform hundreds of anticancer drug testing and can analyze the biological activity of your compound by itself or in combination with known anticancer drugs.
We can order a new cell line and custom develop your assay as per your specific needs.
SBH Sciences is actively collaborating with Karyopharm Therapeutics on its anticancer development program. We have used over 200 cancer cell lines in this collaboration and are continuing to screen for promising anticancer drugs. SBH Sciences and Karyopharm Therapeutics have presented ten scientific abstracts together.
In recent years, the number of peptide-based new chemical entities (NCEs) entering clinical development and receiving approval in the United States and globally has grown significantly. This surge is primarily due to advancements in production and analytical capabilities, which have facilitated the development of larger peptides and expanded the diversity of molecular targets and therapeutic areas.
SBH Science’s is the world leader in cell-based assays to measure the biological activity of cytokines and growth factors. Our services include a diverse array of cell-based disease models, featuring over 380 human cancer cell lines and more than 350 cell-based assays for evaluating cytokine and chemokine activity. Our extensive capabilities position us to offer exceptional assistance to therapeutic companies in their lead drug optimization process, including:
Using our comprehensive bioanalytical technologies, including Luminex and immunological services, we can assess specific antibody production. Based on your needs, we can design, develop, and validate custom assays to meet your exact specifications.
Please contact us with your specific needs or any questions related to In-Vitro Oncology investigation and Peptide Therapeutics lead drug development and optimization.
